NEW YORK, April 10, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of NantHealth, Inc. securities (NASDAQ:NH): (1) pursuant or traceable to NantHealth’s initial public offering on or about June 1, 2016; and/or (2) from June 1, 2016 through March 6, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for NantHealth investors under the federal securities laws.
To join the NantHealth class action, go to http://www.rosenlegal.com/cases-1074.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that: (1) NantHealth founder Patrick Soon-Shiong donated funds through nonprofit organizations to the University of Utah for the purpose of funneling those funds back into NantHealth; (2) as such, NantHealth and Soon-Shiong violated federal tax laws—exposing NantHealth to possible civil and criminal liability; (3) NantHealth improperly recorded orders received from the University of Utah as GPS Cancer test orders; (4) in turn, NantHealth reported false and inflated GPS Cancer order figures for the third quarter of 2016; and (5) as a result, defendants’ statements regarding NantHealth’s outlook and expected financial performance were false and misleading and lack a reasonable basis when made. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1074.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Washington Post Publisher Will Lewis Steps Down After Layoffs
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



